Nicholas Investment Partners LP purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) during the 2nd quarter, HoldingsChannel reports. The firm purchased 186,769 shares of the company’s stock, valued at approximately $18,206,000. Dianthus Therapeutics accounts for about 1.0% of Nicholas Investment Partners LP’s holdings, making the stock its 25th biggest holding.
Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares during the period. UBS Group AG raised its position in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Dianthus Therapeutics by 1,275.3% during the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares during the period. SummitTX Capital L.P. lifted its stake in Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after acquiring an additional 12,118 shares during the period. Finally, California State Teachers Retirement System lifted its stake in Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after acquiring an additional 24,697 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.
Dianthus Therapeutics Trading Down 0.9%
Shares of NASDAQ:DNTH opened at $110.07 on Tuesday. Dianthus Therapeutics, Inc. has a 12-month low of $22.81 and a 12-month high of $117.88. The company has a market capitalization of $6.02 billion, a PE ratio of -26.52 and a beta of 1.22. The business has a 50 day moving average of $101.30 and a two-hundred day moving average of $85.62.
Insider Transactions at Dianthus Therapeutics
In related news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 287,084 shares of company stock worth $29,615,923. Insiders own 3.02% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently weighed in on DNTH shares. HC Wainwright increased their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Raymond James Financial reissued a “strong-buy” rating and set a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.
Get Our Latest Analysis on Dianthus Therapeutics
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report).
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
